Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data

Clinical Nephrology

Volumn 88, Issue 2, 2017, Pages 59-67

  Coyne, Daniel W ^a   Ficociello, Linda H ^b   Parameswaran, Vidhya ^b   Anderson, Ludmila ^b   Vemula, Sharanya ^b   Ofsthun, Norma J ^b   Mullon, Claudy ^b   Maddux, Franklin W ^b   Kossmann, Robert J ^b   Sprague, Stuart M ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Phosphorus; Pill burden; Sucroferric oxyhydroxide

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRIC CITRATE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON SACCHARATE; LANTHANUM CARBONATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PRESCRIPTION DRUG; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; SUCROFERRIC OXYHYDROXIDE; TRANSFERRIN; FERRIC ION; SUCROSE;

ADULT; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CHRONOPHARMACOLOGY; CLEARANCE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EQUILIBRATED KTV; EQUILIBRATED NORMALIZED PROTEIN CATABOLIC RATE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NUTRITIONAL PARAMETERS; PHARMACY; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; RETROSPECTIVE STUDY; TRANSFERRIN SATURATION; TREATMENT DURATION; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; HEMODIALYSIS;

ADULT; AGED; DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SUCROSE;

EID: 85026737166     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN109021     Document Type: Article

References (14)

1. Lertdumrongluk P, Rhee CM, Park J, Lau WL, Moradi H, Jing J, Molnar MZ, Brunelli SM, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K. Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. J Ren Nutr. 2013; 23: 411-421
2. Eknoyan G, Levin A, Levin NW; National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201
3. United States Renal Data System. 2015 USRDS annual data report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015
4. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009; 4: 1089-1096
5. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013; 14: 153
6. Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, Akiba T, Bommer J, Ethier J, Jadoul M, Pisoni RL, Robinson BM, Tentori F. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int. 2016; 20: 38-49
7. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014; 29: 2092-2099
8. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Group PA; PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014; 86: 638-647
9. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015; 30: 1037-1046
10. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010; 74: 4-11
11. Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol. 2016; 27: 2205-2215
12. FDA Drug Safety Communication. Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm. Accessed on March 3, 2016
13. Covic A, Sprague S, Ketteler M, Spinowitz B, Rastogi A, Botha J, Rakov V, Jürgen Floege J. Post Hoc Analysis of IV Iron and ESA Use over 1 Year in a Phase 3 Study of Sucroferric Oxyhydroxide. Poster Presentation, ERA EDTA, 52 Congress, London, UK, May 2015
14. National Kideny Foundation. K/DOQI Guidelines for CKD Care: nutrition in chronic renal railure. Am J Kidney Dis. 2000; 35 (Suppl 2): S1-S11